[Immuno-Oncology Newsletter] Tackling Cancer with Gene & Cell Therapy: The Next Frontier

Immuno-Oncology Insights: The Rise of Gene Therapy

The gene therapy market is experiencing significant growth, marking a shift towards personalised and targeted medicine. Although there are currently only 12 in vivo gene therapy products on the market, this landscape is expected to evolve rapidly in the coming years, with over 2,135 gene therapies in development and a projected 20% annual growth until 2030.

Gene therapy is still in its early stages, with 85% of projects in preclinical development. Its strength lies in targeting a wide range of diseases (genetic and metabolic disorders, oncology, and ophthalmology), supported by adeno-associated vectors (AAVs), which dominate the field due to their safety and efficiency in gene delivery.

Despite early-stage challenges, gene therapies are set to revolutionise precision medicine, offering new hope for patients in the coming years.

_{(Source: MabDesign.fr , Market Analysis – Thérapies géniques. Published on January 6th 2025.)}

Blog: Optimising mRNA Therapies: A Game-Changer for Immuno-Oncology!

mRNA-based therapies are transforming cancer treatment, but optimised design is the key to unlocking their full potential.

CleanCap® Technology and minimal UTRs play crucial roles in enhancing mRNA stability, boosting protein expression, and ensuring a stronger, more sustained immune response—essential for next-generation immuno-oncology breakthroughs. 

Want to harness the power of optimised mRNA for your immuno-oncology research? Discover the latest innovations now!

Tebubio Contract Research Services: Optimising mRNA Delivery: Unleashing the Full Potential of LNPs

 
Lipid nanoparticles (LNPs) have revolutionised nucleic acid-based drug delivery, providing stability and enhanced cellular uptake.

At Tebubio, we have tested and optimised various lipid formulations from leading suppliers to maximise mRNA encapsulation and transfection efficiency. Our study explores the impact of LNP composition on delivery performance in different cell models, offering key insights for your research.

Discover how to optimise LNP formulations and enhance your mRNA delivery efficiency with the expertise of Tebubio’s project managers!

Stimulus solutions

^{CDD-2789 (3052084-77-9)}

Struggling to overcome immune evasion and tumour progression in your oncology research?

CDD-2789, from our trusted partner Focus Biomolecule, is the first-to-market solution designed to target TGF-β, a critical regulator of the tumour microenvironment. By disrupting key pathways involved in cancer proliferation and immunosuppression, this cutting-edge compound empowers you to explore new therapeutic frontiers. Whether you're advancing preclinical models or refining translational approaches, this inhibitor provides the precision your research demands.

Stay ahead of the curve—integrate CDD-2789 into your pipeline today!

Models solutions

^{Lympholyte® Cell Separation Media}

Improve Lymphocyte Isolation for Reliable Immuno-Oncology Research.

Efficient lymphocyte isolation is essential for cancer immunotherapy, cytotoxicity studies, and immune profiling. However, traditional methods often lead to low yields, contamination, or reduced cell viability.

Lympholyte® Cell Separation Media from Cedarlane enables high recovery rates of viable lymphocytes from various species, including human, mouse, rat, and rabbit. Designed for FACS assays, cytotoxicity tests, and in vivo/in vitro studies, Lympholyte® ensures precision and reliability in your research.

Optimise your cell isolation process today!

Analysis solutions

Struggling with Cell Viability Assays?

Measuring cancer cell survival and drug responses can be challenging with traditional assays that are costly or complex. The LIVE-Step™ Cell Assay System from our partner BPS Bioscience provides a fast, one-step luminescence-based solution—ideal for high-throughput screening and reliable cytotoxicity assessments.

Optimize your immuno-oncology research today!

We facilitate Life Sciences Research daily, advancing Science for a brighter future with comprehensive biological solutions from top global suppliers to accelerate your research projects.

If you lack time or expertise, our CRS team can support you with mRNA production, cell line engineering, protein production, cellular studies, and biomarker analysis.

With Tebubio, concentrate your efforts and accelerate what’s most important to you: your research.

Stay Ahead in Immuno-Oncology

Subscribe to our monthly newsletter for the latest breakthroughs, expert insights, and exclusive updates in immuno-oncology.